Lilly India enters the autoimmune segment with Olumiant
Eli Lilly and Company (India) Pvt. Ltd. (Lilly India) has announced the launch of Olumiant (baricitinib), marking the company’s entry into the autoimmune segment in India.
Olumiant (baricitinib) is a once-daily oral medication for the treatment of adults with moderate-to-severe active Rheumatoid Arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Olumiant may be used as monotherapy or in combination with methotrexate.
Olumiant will be available in India starting October 2018 in 4mg and 2mg dosage forms. It is approved in more than 50 countries across the world.
Luca Visini, Managing Director, Eli Lilly and Company India, said, "Few days ahead of World Arthritis Day, Lilly India is excited to announce the introduction of its innovative therapy for patients living with Rheumatoid Arthritis. It is an announcement that builds on our heritage and commitment to India, a 25 years strong legacy of making life better and addressing the unmet needs of patients living with chronic diseases."
"People with Rheumatoid Arthritis continue to struggle with the debilitating effects of the disease, endure pain and do not achieve disease management goals. This can lead to long-term joint damage and even disability. Olumiant is an effective, advanced once-daily oral treatment option for people suffering from Rheumatoid Arthritis who have not responded well to conventional DMARDs. In clinical trials, Olumiant has proven efficacy and demonstrated rapid and significant improvement in patient-related outcomes such as pain, fatigue and joint stiffness," he added.